ReviewFrontiers in immunology2026
Molecular mechanisms and clinical significance of the glioma metabolic-immune axis: a comprehensive review.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic immune checkpoints in cancer: how tumor-derived metabolites shape immunotherapy resistance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma is the most common and highly aggressive tumor of the central nervous system. Increasing evidence indicates that metabolic reprogramming and the tumor immune microenvironment are intricately interconnected and jointly contribute to tumor initiation, progression, and therapeutic resistance. In recent years, advances in multi-omics technologies have revealed that multiple metabolic pathways-including nucleotide, amino acid, and lipid metabolism-are closely associated with immune cell infiltration, immune evasion, and clinical outcomes in glioma, leading to the emergence of the "metabolic-immune axis" concept. This review systematically summarizes the regulatory mechanisms by which metabolic reprogramming shapes the glioma immune microenvironment and highlights key metabolic genes and immune phenotypes as potential molecular biomarkers for prognosis prediction and immunotherapeutic response. We further discuss multi-omics-based glioma classification strategies, the mechanistic roles of metabolic pathways in immune escape, and the therapeutic potential of combining metabolic-targeted interventions with immunotherapy. By integrating current research advances and existing challenges, this review aims to provide a comprehensive framework for understanding the metabolic-immune interplay in glioma and to identify promising targets for precision therapy and future clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.